We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
For HIV vaccine trials, size does matter.
- Authors
Erickson, Amy K.
- Abstract
This article reports an announcement made by California-based VaxGen in February 2003 that its HIV vaccine selectively protects blacks from infection, experts questioned the statistical significance of results. Out of the resulting controversy has emerged a real push to change the way minorities are recruited and retained in HIV vaccine trials. In response to VaxGen's announcement, the U.S. National Institutes of Health working group reanalyzed the data and concluded that the protective effect observed in certain subgroups was a fluke. The group said that the minority population in the trial was too small to detect any differences.
- Subjects
UNITED States; AIDS vaccines; VAXGEN Inc.; MINORITIES; LENTIVIRUS diseases; NATIONAL Institutes of Health (U.S.)
- Publication
Nature Medicine, 2004, Vol 10, Issue 2, p111
- ISSN
1078-8956
- Publication type
Article
- DOI
10.1038/nm0204-111b